← Back to Home

Gene Silencing Still Awaits Human Validation as Scribe Upsizes IPO to Raise $128.7 Million

Capital markets are betting on a one-time lipid-lowering therapy; lead program STX-1150 does not cut DNA, but instead suppresses PCSK9 expression, although the first human data will not be disclosed until the first half of 2027.

By SURL BioNews

Despite having yet to produce its first human efficacy data, Scribe Therapeutics successfully upsized its initial public offering, showing that investors are willing to assume early-stage risk for a new generation of cardiovascular genetic medicines. The company sold 8.58 million shares at $15 per share, the upper end of its originally proposed price range, raising approximately $128.7 million; the funding will advance its in-vivo CRISPR platform toward a critical stage of clinical validation.

The offering included approximately 1.4 million more shares than originally planned. Scribe shares will trade on Nasdaq under the ticker SCTX, while Sanofi separately agreed to a concurrent $7.5 million private placement. Renaissance Capital data also show that existing shareholder Eli Lilly plans to participate in the public offering, bringing its post-listing ownership stake to 10.9%; the investments by the two major pharmaceutical companies provide Scribe with strategic backing, but do not mean that its therapeutic candidates have been proven effective.

The focus of the fundraising is the Phase 1 clinical program STX-1150. It targets PCSK9—a gene that affects the liver’s ability to clear low-density lipoprotein cholesterol—and shuts down its expression epigenetically. Unlike gene editing that directly cuts or rewrites DNA sequences, this approach seeks to durably reduce PCSK9 and low-density lipoprotein cholesterol without permanently changing the DNA text.

This distinction underpins Scribe’s central proposition: if a single in-vivo treatment can maintain stable lipid reduction, patients may not need long-term medication or regular injections. However, “not permanently rewriting DNA” does not mean that risks have been eliminated; how long the gene silencing can persist, whether the dose is sufficient to produce clinical significance, and the safety of delivery and unintended effects must all be answered through human studies.

STX-1150 has now entered a first-in-human trial under authorization from Australia’s Therapeutic Goods Administration, with preliminary data expected in the first half of 2027. This will be an important milestone in determining whether Scribe’s technology can move from a molecular mechanism to a usable medicine; at present, there are no human efficacy or long-term safety data, nor can it be inferred from the available information that the treatment can reduce the risk of myocardial infarction or stroke.

The company also plans to use STX-1200 to lower lipoprotein(a) and STX-1400 to address triglyceride-related risk, with the programs expected to enter Phase 1 trials in 2027 and 2028, respectively. The upsized IPO has bought time for this pipeline, but its value will ultimately be determined by whether STX-1150 can deliver the magnitude, durability, and safety of lipid reduction in humans.

References

  1. Renaissance Capital